Dr Roy Baynes | Senior Vice President And Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme (MSD)

Dr Roy Baynes, Senior Vice President And Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme (MSD)

Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Research Laboratories. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.

Appearances:



Conference Day 2: Friday 17th May 2019 @ 10:00

Keynote panel: Innovations in cellular and combination immunotherapy: current learnings, challenges and future applications

· Using the immune system to identify and fight cancer cells: where are we and what do we need to maximise patient benefit in the future?· Improving cellular immunotherapy success by using genetic biomarkers to create precision medicines and improve success rates· Where are we with combination immunotherapy, what needs to be done to improve efficiency and effectiveness in the future. · Moving from oncology to non-oncology applications, how can we make the shift to new therapy indications· Preventing relapse and resistance
last published: 21/Mar/19 09:25 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.

TO SPONSOR / EXHIBIT

Erica Baeta 
+44 (0)207 092 1152 
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson 
t/ +44 (0)207 092 1150 
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor 
+44 (0)207 092 1257 
issa.mauthoor@terrapinn.com